» Articles » PMID: 29269524

New Pathogenic Mechanisms Induced by Germline Erythropoietin Receptor Mutations in Primary Erythrocytosis

Abstract

Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the erythropoietin hypersensitivity phenotype. Here we provide evidence for a new mechanism whereby the presence of novel sequences generated by frameshift mutations is required for the phenotype rather than just extensive truncation resulting from nonsense mutations. We show that the erythropoietin hypersensitivity induced by a new erythropoietin receptor mutant, p.Gln434Profs*11, could not be explained by the loss of negative signaling and of the internalization domains, but rather by the appearance of a new C-terminal tail. The latter, by increasing erythropoietin receptor dimerization, stability and cell-surface localization, causes pre-activation of erythropoietin receptor and JAK2, constitutive signaling and hypersensitivity to erythropoietin. Similar results were obtained with another mutant, p.Pro438Metfs*6, which shares the same last five amino acid residues (MDTVP) with erythropoietin receptor p.Gln434Profs*11, confirming the involvement of the new peptide sequence in the erythropoietin hypersensitivity phenotype. These results suggest a new mechanism that might be common to erythropoietin receptor frameshift mutations. In summary, we show that primary familial and congenital polycythemia is more complex than expected since distinct mechanisms are involved in the erythropoietin hypersensitivity phenotype, according to the type of erythropoietin receptor mutation.

Citing Articles

Benefit of phlebotomy and low-dose aspirin in the prevention of vascular events in patients with primary familial polycythemia on the island of New Caledonia.

Boulnois L, Robles M, Maaziz N, Aral B, Gauthier M, Duchene F Haematologica. 2024; 109(8):2688-2692.

PMID: 38546672 PMC: 11290533. DOI: 10.3324/haematol.2023.284658.


Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins.

Liongue C, Ward A Cancers (Basel). 2024; 16(2).

PMID: 38254802 PMC: 10813624. DOI: 10.3390/cancers16020313.


ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis.

Basso-Valentina F, Donada A, Manchev V, Lisetto M, Balayn N, Martin J Haematologica. 2023; 108(8):2130-2145.

PMID: 36794499 PMC: 10388282. DOI: 10.3324/haematol.2022.282049.


Identification of Two Novel Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review.

Lo Riso L, Vargas-Parra G, Navarro G, Arenillas L, Fernandez-Ibarrondo L, Robredo B Genes (Basel). 2022; 13(10).

PMID: 36292571 PMC: 9601602. DOI: 10.3390/genes13101686.


Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.

Bhai P, Chin-Yee B, Pope V, Cheong I, Matyashin M, Levy M Curr Oncol. 2022; 29(10):7209-7217.

PMID: 36290845 PMC: 9600330. DOI: 10.3390/curroncol29100568.


References
1.
Bento C, Almeida H, Maia T, Relvas L, Oliveira A, Rossi C . Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). Eur J Haematol. 2013; 91(4):361-8. DOI: 10.1111/ejh.12170. View

2.
Witthuhn B, Quelle F, Silvennoinen O, Yi T, Tang B, Miura O . JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993; 74(2):227-36. DOI: 10.1016/0092-8674(93)90414-l. View

3.
Watowich S, Xie X, Klingmuller U, Kere J, Lindlof M, Berglund S . Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood. 1999; 94(7):2530-2. View

4.
Sulahian R, Cleaver O, Huang L . Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood. 2009; 113(21):5287-97. PMC: 2686193. DOI: 10.1182/blood-2008-09-179572. View

5.
Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, Rossi F . EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One. 2010; 5(8):e12015. PMC: 2916842. DOI: 10.1371/journal.pone.0012015. View